Medical device organizations are continuing to sharpen their focus on developing high-quality medical devices aimed at improving patient outcomes. However, industry’s hyper-focus on compliance often becomes an obstacle to improving quality and innovation.
A recent study was conducted to assess the industry’s ability to build a culture of quality and innovation. For this research, trends were identified and analyzed, along with requirements and initiatives that organizations are undertaking to proactively manage products and platforms across the product lifecycle.
In support of the research, 110 medical device professionals were surveyed and one-on-one interviews and group discussions were conducted with 23 industry executives representing 59 medical device manufacturers from 12 countries.
Research shows that most organizations continue to identify the primary role of QA as compliance—ensuring documentation and adherence to regulatory requirements and with internal policies and procedures. However, the true focus of QA should be on improving product quality. Closing the loop allows quality and compliance events to influence the product engineering cycle in a timely fashion.
85% of respondents indicated the primary role of quality is ensuring compliance
10% of respondents said the primary role of quality is to drive product / process improvement
31% of executives report closing the loop most of the time when addressing a quality event
Key Research Takeaways
While quality is valued differently by different sets of stakeholders, quality and compliance are often confused. Different roles hold differing viewpoints on how quality is measured, who is responsible, and the role of compliance in ensuring quality.
Medical device makers are still struggling to close the quality gap. Industry’s approach to quality is changing as organizations work to harmonize business processes across business units.
Industry leaders are increasingly shifting to modern closed-loop quality platforms. A closed loop approach not only improves product quality across the total product lifecycle, but also encourages collaboration and visibility.
Engaging PLM and QM early in the design-to-release process drives down the cost of quality. Companies that effectively close the loop from quality and compliance processes and feed that information back into manufacturing and engineering systems will be best situated to meet patient needs.
To compete in today’s global markets, medical device companies must shift to modern, closed loop, product development approaches. They must also change their approach from simply meeting compliance requirements to managing critical to quality data with visibility across the total product lifecycle. A unified approach can help medical device makers make this crucial shift by enabling better collaboration, visibility and product quality across the total lifecycle.
Taking these compliance challenges into account will allow healthcare organizations to prepare for compliance audits, but more importantly it will help institutions address issues that result in a negative patient outcome.
On May 16-17, the MedTech Regulatory Intelligence Summit will bring regulatory affairs professionals and members of the FDA together for two days of education, discussion and networking as we look at challenges and best practices in navigating current and on…
Jordi labs and its team of Ph.D. analytical chemists developed a proprietary, multi-detector approach to ensure that all extractables are accurately characterized to comply with global materials testing regulatory requirements.
The purpose of the Best Practices in Supply Chain Resiliency and Quality Working Group is to improve medical device quality and supply chain resiliency by expanding MedAccred adoption through the tiers in the supply chain, identifying best practices to supplement…
Daniel R. Matlis is founder and president of Axendia, an analyst firm providing advice to life science and healthcare executives on business, technology and regulatory matters. He has almost three decades of industry experience spanning the health-science value chain. He has been an active member in FDA’s Case for Quality Initiative since 2014 and has presented Axendia’s research findings to industry executives and the FDA officials.
Matlis began his career at Johnson & Johnson, where he provided leadership in the areas of technology, regulatory compliance and business. Before founding Axendia, Matlis was a partner, VP and general manager at a leading life science consultancy firm. He is a frequent lecturer at industry events and has published numerous research reports and articles on key issues facing the life sciences and healthcare industries.
Matlis holds a BS in electrical engineering from Polytechnic University (now NYU School of Engineering) in NY and a MS in management from the New Jersey Institute of Technology.